Bio-Reference Labs

According to a recent report from Benchmark, revenue for Bio-Reference Labs (NASDAQ: BRLI) was up over 24% for F2Q11, exceeding the consensus and forecast previously predicted for the company. Due to these earnings, Benchmark is increasing the price target from $25.00 to $29.00. In the report,...